{'fraction_non_alphanumeric': 0.021439509954058193, 'fraction_numerical': 0.02909647779479326, 'mean_word_length': 5.349514563106796, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The localization of anti-tumour monoclonal antibodies in colorectal cancer.

The localization of antitumour monoclonal antibodies was studied in patients with colorectal cancer after intravenous injection. The monoclonal antibody 791T/36 was shown to localise in primary and secondary disease with a preferential uptake of 2.5:1 compared with normal colon. Improved imaging properties were achieved by changing the radiolabel from 131I to 111In and by emission tomography. Using an anti-CEA antibody, C46, a preferential rate of uptake of 5.8:1 was achieved giving superior images and enhancing the prospects of effective targeting of antitumour agents.